✦ LIBER ✦

Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer

✍ Scribed by Howard I. Scher; David Kelsen; Leonard Kalman; Larry Jones; Joseph Burchenal; Richard Gralla

Book ID: 104684893
Publisher: Springer
Year: 1984
Tongue: English
Weight: 349 KB
Volume: 12
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254599

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of alternating 4 chemothe

Phase II trial of alternating 4 chemotherapy regimens in non-small cell lung cancer

✍ Stewart, D.J; Shamji, F; Maziak, D; MacLeod, P; Tomiak, E 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 107 KB

A phase II trial of chlorambucil in non-

A phase II trial of chlorambucil in non-small cell lung cancer

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Phase II study of S-1 monotherapy in pla

Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer

✍ Shiroyama, Takayuki; Komuta, Kiyoshi; Imamura, Fumio; Hirashima, Tomonori; Kijim 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 259 KB

Phase II trial of VP16-213 in non-small

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

✍ Robert Chapman; Loretta Itri; Richard Gralla; David Kelsen; Ephraim Casper; Robe 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 238 KB

A phase II trial of oral 4′ demethoxydau

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

✍ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat